By disrupting the clinical trials process, the Covid-19 pandemic has served as a tipping point to advance decentralized clinical trials (DCTs) and other innovations in managing these essential studies.
To date, but primarily during the pandemic, most of the decentralized-related innovation has centered around infrastructure and process, mainly addressing the patient burdens and geographic barriers related to time, travel, and logistics. There’s been far less innovation on another key part of trial management: patient recruitment and retention, linchpins of clinical research.
Create a display name to comment
This name will appear with your comment
